Renato Alves

Project Advisor

Pelago Bioscience

Thomas Geiger

Scientist

TU Darmstadt

Katelyn Cassidy

UPS Biology, Proteomics Scientist

C4 Therapeutics

Ingrid Wertz

CEO & Co-Founder

Lyterian Therapeutics

Clone of Ingrid Wertz

Executive Director, Protein Homeostasis Center of Excellence

BMS

Ingrid E. Wertz is the Executive Director of the Protein Homeostasis Center of Excellence at Bristol Myers Squibb. She obtained her undergraduate degree in Molecular and Cellular Biology from the University of California at Berkeley, performed her graduate studies at Genentech via an NIH Biotechnology Training Grant from U.C. Davis, and received her M.D. from Washington University in St. Louis as a Medical Scientist Training Program fellow. Dr. Wertz was a recipient of the Harold M. Weintraub Graduate Student Award. Prior to joining BMS in May of 2021, Dr. Wertz was a Principal Scientist at Genentech. There she served as the Biology Lead for BCL-2 family antagonists that contributed to venetoclax, she was the initial Biology Lead for the selective estrogen receptor degrader (SERDs) program that contributed to giredistrant, she led USP7 inhibitor drug discovery teams, and co-initiated and led the Genentech Degrader Platform. Dr. Wertz’s research is primarily focused on elucidating the molecular mechanisms of therapeutic compounds and co-opting the Ubiquitin System for therapeutic benefit.

Steven Edenson

Strategic Collaborations Manager

Promega

Caroline Rynn

DMPK-PD Project Leader, Senior Principal Scientist

Roche

Axel Vicart

Director of Mechanistic Safety

Novartis